Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FiGhTeR trial of pemigatinib in trastuzumab-resistant advanced gastric or EGJ cancer
2017-004522-14Phase 2Terminated
- Sponsor
- Centro Ricerche Cliniche di Verona Srl
- Start
- Jan 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemigatinib in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Centro Ricerche Cliniche di Verona Srl. Primary endpoint: 12-week progression-free survival rate. Started Jan 2019; status: terminated.
02
Drugs
pemigatinib
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2017-004522-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004522-14.